for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aeglea Bio Therapeutics Inc

AGLE.OQ

Latest Trade

7.82USD

Change

-0.08(-1.01%)

Volume

11,198

Today's Range

7.64

 - 

7.90

52 Week Range

5.99

 - 

10.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.90
Open
7.81
Volume
11,198
3M AVG Volume
1.75
Today's High
7.90
Today's Low
7.64
52 Week High
10.12
52 Week Low
5.99
Shares Out (MIL)
28.89
Market Cap (MIL)
225.88
Forward P/E
-3.48
Dividend (Yield %)
--

Latest Developments

More

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

Aeglea Biotherapeutics Reports Second Quarter 2019 Financial Results And Corporate Highlights

Aeglea Biotherapeutics Receives FDA Breakthrough Therapy Designation For Pegzilarginase

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aeglea Bio Therapeutics Inc

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Industry

Biotechnology & Drugs

Contact Info

901 S. Mopac Expressway

Ste. 250, Barton Oaks Plaza One

+1.512.9422935

http://aegleabio.com

Executive Leadership

Russell J. Cox

Independent Chairman of the board

Anthony G. Quinn

President, Chief Executive Officer, Chief Medical Officer, Director

Charles N. York

Chief Financial Officer, Vice President

Leslie Sloan

Chief Operating Officer

Aaron Schuchart

Chief Business Officer

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.220

2017

-1.800

2018

-2.130

2019(E)

-2.246
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.03
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-69.66
Return on Equity (TTM)
-62.88

Latest News

Latest News

BRIEF-Aeglea Biotherapeutics Announces Proposed Public Offering

* AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

BRIEF-Aeglea BioTherapeutics reports Q2 loss per share $0.47

* Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up